Adial Pharmaceuticals Acquires Azora and Raises Up to $64 Million for New Ulcerative Colitis Drug

Adial Pharmaceuticals acquires Azora Therapeutics and raises up to $64 million to advance AT177, a novel colon-targeted therapy for ulcerative colitis. Phase 1 studies planned for mid-2027.